Use of Onasemnogene Abeparvovec gene therapy for Spinal Muscular Atrophy

Spinal muscle atrophy (SMA) is an autosomal recessive and neurodegenerative disease caused by homozygous mutations in the survival motor neuron1(SMN 1) gene. SMA isdistinguished by motor neuron degeneration, which is a resulting in weakness and increasing muscle atrophy. Children with a most severe form of SMA there were not able to sit independently.There was only 8% of children would survivebeyond their 2years of age without permanent ventilation support. One of these therapies, Onasemnogene abeparvovec, a gene replacement therapy based on the adeno-related virus, is a one-time intravenous infusion in which it delivers human function SMA. Inadditionto significantly improving survival, Onasemnogene Abeparvovec increases motor function and reducesthe need for respiratory or nutritional support in many patients. Recommendations of Dosage and administration. Recommendations for Prophylaxis of prednisolone tapering and monitoring for potential adverse events, including hepatotoxicity, Elevated Troponin -I thrombotic microangiopathy, are described here.